153 related articles for article (PubMed ID: 6927729)
21. Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy.
Iwamoto Y; Kosaka K; Kuzuya T; Akanuma Y; Shigeta Y; Kaneko T
Diabetes Care; 1996 Feb; 19(2):151-6. PubMed ID: 8718436
[TBL] [Abstract][Full Text] [Related]
22. Glycemic control in a sample of black and white clinic patients with NIDDM.
Weatherspoon LJ; Kumanyika SK; Ludlow R; Schatz D
Diabetes Care; 1994 Oct; 17(10):1148-53. PubMed ID: 7821134
[TBL] [Abstract][Full Text] [Related]
23. The feasibility of intensive insulin management in non-insulin-dependent diabetes mellitus. Implications of the Veterans Affairs Cooperative Study on Glycemic Control and Complications in NIDDM.
Colwell JA
Ann Intern Med; 1996 Jan; 124(1 Pt 2):131-5. PubMed ID: 8554205
[TBL] [Abstract][Full Text] [Related]
24. Acarbose in NIDDM patients with poor control on conventional oral agents. A 24-week placebo-controlled study.
Lam KS; Tiu SC; Tsang MW; Ip TP; Tam SC
Diabetes Care; 1998 Jul; 21(7):1154-8. PubMed ID: 9653611
[TBL] [Abstract][Full Text] [Related]
25. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.
Robinson AC; Burke J; Robinson S; Johnston DG; Elkeles RS
Diabetes Care; 1998 May; 21(5):701-5. PubMed ID: 9589227
[TBL] [Abstract][Full Text] [Related]
26. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus.
Turner R; Cull C; Holman R
Ann Intern Med; 1996 Jan; 124(1 Pt 2):136-45. PubMed ID: 8554206
[TBL] [Abstract][Full Text] [Related]
27. The effect of high- and low-glycemic index energy restricted diets on plasma lipid and glucose profiles in type 2 diabetic subjects with varying glycemic control.
Heilbronn LK; Noakes M; Clifton PM
J Am Coll Nutr; 2002 Apr; 21(2):120-7. PubMed ID: 11999539
[TBL] [Abstract][Full Text] [Related]
28. Long-term glycemic control measurements in diabetic patients receiving hemodialysis.
Joy MS; Cefalu WT; Hogan SL; Nachman PH
Am J Kidney Dis; 2002 Feb; 39(2):297-307. PubMed ID: 11840370
[TBL] [Abstract][Full Text] [Related]
29. A double-masked placebo-controlled trial assessing effects of various doses of BTS 67,582, a novel insulinotropic agent, on fasting hyperglycemia in NIDDM patients.
Skillman CA; Raskin P
Diabetes Care; 1997 Apr; 20(4):591-6. PubMed ID: 9096985
[TBL] [Abstract][Full Text] [Related]
30. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study.
Coniff RF; Shapiro JA; Robbins D; Kleinfield R; Seaton TB; Beisswenger P; McGill JB
Diabetes Care; 1995 Jun; 18(6):817-24. PubMed ID: 7555508
[TBL] [Abstract][Full Text] [Related]
31. 1,5-Anhydro-D-glucitol evaluates daily glycemic excursions in well-controlled NIDDM.
Kishimoto M; Yamasaki Y; Kubota M; Arai K; Morishima T; Kawamori R; Kamada T
Diabetes Care; 1995 Aug; 18(8):1156-9. PubMed ID: 7587851
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of glycemic control in patients with type 2 diabetes mellitus in Chinese communities: a cross-sectional study.
Shan S; Gu L; Lou Q; Ouyang X; Yu Y; Wu H; Bian R
Clin Exp Med; 2017 Feb; 17(1):79-84. PubMed ID: 26695015
[TBL] [Abstract][Full Text] [Related]
33. Outcomes in weight loss, fasting blood glucose and glycosylated hemoglobin in a sample of 415 obese patients, included in the database of the European accreditation council for excellence centers for bariatric surgery with laparoscopic one anastomosis gastric bypass.
Carbajo MA; Jiménez JM; Castro MJ; Ortiz-Solórzano J; Arango A
Nutr Hosp; 2014 Nov; 30(5):1032-8. PubMed ID: 25365005
[TBL] [Abstract][Full Text] [Related]
34. Using glycosylated hemoglobin to define the metabolic syndrome in United States adults.
Ong KL; Tso AW; Lam KS; Cherny SS; Sham PC; Cheung BM
Diabetes Care; 2010 Aug; 33(8):1856-8. PubMed ID: 20504895
[TBL] [Abstract][Full Text] [Related]
35. The Fasting Hyperglycaemia Study: I. Subject identification and recruitment for a non-insulin-dependent diabetes prevention trial.
Hammersley MS; Meyer LC; Morris RJ; Manley SE; Turner RC; Holman RR
Metabolism; 1997 Dec; 46(12 Suppl 1):44-9. PubMed ID: 9439559
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic utility of glycosylated hemoglobin concentrations in the cat.
Hoenig M; Ferguson DC
Domest Anim Endocrinol; 1999 Jan; 16(1):11-7. PubMed ID: 10081659
[TBL] [Abstract][Full Text] [Related]
37. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM).
Abraira C; Henderson WG; Colwell JA; Nuttall FQ; Comstock JP; Emanuele NV; Levin SR; Sawin CT; Silbert CK
Diabetes Care; 1998 Apr; 21(4):574-9. PubMed ID: 9571345
[TBL] [Abstract][Full Text] [Related]
38. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
[TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of normalizing fasting glucose with bedtime NPH insulin alone in NIDDM.
Cusi K; Cunningham GR; Comstock JP
Diabetes Care; 1995 Jun; 18(6):843-51. PubMed ID: 7555511
[TBL] [Abstract][Full Text] [Related]
40. Blood ketone bodies in NIDDM: relationship with diabetic control and endogenous insulin secretion.
Suzuki M; Kosegawa I; Miura S; Negishi K; Itabashi A; Katayama S; Ishii J; Kamata S; Fujita C
Diabetes Res; 1991 Sep; 18(1):11-7. PubMed ID: 1823641
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
